Thursday, 5 November 2026European Markets

ALUMEXX N.V. Stock Went Down By Over 21% In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of ALUMEXX N.V. (AEX-Index: ALX.AS) slid by a staggering 21.28% in 10 sessions from €0.69 to €0.54 at 11:06 EST on Monday, following the last session's downward trend. AEX-Index is falling 0.15% to €760.27, after two consecutive sessions in a row of gains.

ALUMEXX N.V.'s last close was €0.56, 36.94% under its 52-week high of €0.89.

About ALUMEXX N.V.

Alumexx N.V. manufactures and sells scaffoldings, stairs, ladders, accessories, and tools for indoor or outdoor use in the Netherlands and internationally. The company was formerly known as Phelix N.V. and changed its name to Alumexx N.V. in January 2018. Alumexx N.V. was founded in 1991 and is based in Etten-Leur, the Netherlands.

Earnings Per Share

As for profitability, ALUMEXX N.V. has a trailing twelve months EPS of €0.02.

PE Ratio

ALUMEXX N.V. has a trailing twelve months price to earnings ratio of 26.75. Meaning, the purchaser of the share is investing €26.75 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.5%.

More news about ALUMEXX N.V. (ALX.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com
ALUMEXX N.V. Stock Went Down By Over 21% In The Last 10 Sessions | ViaNews EU